The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up

Minkyu Jung, Hyun Joon Shin, SunYoung Rha, Hei Cheul Jeung, Soojung Hong, Yong Wha Moon, Hyo Song Kim, Kyung Jin Oh, Woo Ick Yang, Jae Kyung Roh, Hyuncheol Chung

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: We investigated the factors that predict chemotherapy-induced amenorrhea (CIA) and the prognostic significance of CIA after long-term follow-up. Methods: We reviewed data from 241 premenopausal patients with breast cancer who underwent adjuvant CMF or FAC chemotherapy after breast cancer surgery between January 1995 and December 2000. Results: The median follow-up duration was 109.8 (range, 16.6-193.1) months. The age of CIA patients was older than non-CIA patients (median, 44 (range, 28-53) years and 36 (range, 25-49) years, respectively; P < 0.001). The addition of tamoxifen to the chemotherapy increased the incidence of CIA from 48% to 63.6% (P = 0.015). The 10-year disease-free survival (DFS) rate was higher in the CIA group compared with the non-CIA group in hormonal receptor-positive patients (78.4% vs. 67%, respectively; P = 0.022), and the 10-year overall survival (OS) rate also was higher in the CIA group compared with the non-CIA group (90.8% vs. 79.7%, respectively; P = 0.041). Conclusions: The most important predictors of CIA are age and the addition of tamoxifen to the chemotherapy. CIA is likely to have an influence on DFS and OS in premenopausal patients with breast cancer with a positive hormone receptor, and it might be used as a surrogate marker for effective chemotherapy in these young Asian patients.

Original languageEnglish
Pages (from-to)3259-3268
Number of pages10
JournalAnnals of Surgical Oncology
Volume17
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Amenorrhea
Breast Neoplasms
Drug Therapy
Tamoxifen
Disease-Free Survival
Survival Rate
Biomarkers
Hormones

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Jung, Minkyu ; Shin, Hyun Joon ; Rha, SunYoung ; Jeung, Hei Cheul ; Hong, Soojung ; Moon, Yong Wha ; Kim, Hyo Song ; Oh, Kyung Jin ; Yang, Woo Ick ; Roh, Jae Kyung ; Chung, Hyuncheol. / The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 12. pp. 3259-3268.
@article{5a7460454f2f45e4a5984ba36e12051f,
title = "The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up",
abstract = "Background: We investigated the factors that predict chemotherapy-induced amenorrhea (CIA) and the prognostic significance of CIA after long-term follow-up. Methods: We reviewed data from 241 premenopausal patients with breast cancer who underwent adjuvant CMF or FAC chemotherapy after breast cancer surgery between January 1995 and December 2000. Results: The median follow-up duration was 109.8 (range, 16.6-193.1) months. The age of CIA patients was older than non-CIA patients (median, 44 (range, 28-53) years and 36 (range, 25-49) years, respectively; P < 0.001). The addition of tamoxifen to the chemotherapy increased the incidence of CIA from 48{\%} to 63.6{\%} (P = 0.015). The 10-year disease-free survival (DFS) rate was higher in the CIA group compared with the non-CIA group in hormonal receptor-positive patients (78.4{\%} vs. 67{\%}, respectively; P = 0.022), and the 10-year overall survival (OS) rate also was higher in the CIA group compared with the non-CIA group (90.8{\%} vs. 79.7{\%}, respectively; P = 0.041). Conclusions: The most important predictors of CIA are age and the addition of tamoxifen to the chemotherapy. CIA is likely to have an influence on DFS and OS in premenopausal patients with breast cancer with a positive hormone receptor, and it might be used as a surrogate marker for effective chemotherapy in these young Asian patients.",
author = "Minkyu Jung and Shin, {Hyun Joon} and SunYoung Rha and Jeung, {Hei Cheul} and Soojung Hong and Moon, {Yong Wha} and Kim, {Hyo Song} and Oh, {Kyung Jin} and Yang, {Woo Ick} and Roh, {Jae Kyung} and Hyuncheol Chung",
year = "2010",
month = "12",
day = "1",
doi = "10.1245/s10434-010-1172-3",
language = "English",
volume = "17",
pages = "3259--3268",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "12",

}

The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. / Jung, Minkyu; Shin, Hyun Joon; Rha, SunYoung; Jeung, Hei Cheul; Hong, Soojung; Moon, Yong Wha; Kim, Hyo Song; Oh, Kyung Jin; Yang, Woo Ick; Roh, Jae Kyung; Chung, Hyuncheol.

In: Annals of Surgical Oncology, Vol. 17, No. 12, 01.12.2010, p. 3259-3268.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up

AU - Jung, Minkyu

AU - Shin, Hyun Joon

AU - Rha, SunYoung

AU - Jeung, Hei Cheul

AU - Hong, Soojung

AU - Moon, Yong Wha

AU - Kim, Hyo Song

AU - Oh, Kyung Jin

AU - Yang, Woo Ick

AU - Roh, Jae Kyung

AU - Chung, Hyuncheol

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background: We investigated the factors that predict chemotherapy-induced amenorrhea (CIA) and the prognostic significance of CIA after long-term follow-up. Methods: We reviewed data from 241 premenopausal patients with breast cancer who underwent adjuvant CMF or FAC chemotherapy after breast cancer surgery between January 1995 and December 2000. Results: The median follow-up duration was 109.8 (range, 16.6-193.1) months. The age of CIA patients was older than non-CIA patients (median, 44 (range, 28-53) years and 36 (range, 25-49) years, respectively; P < 0.001). The addition of tamoxifen to the chemotherapy increased the incidence of CIA from 48% to 63.6% (P = 0.015). The 10-year disease-free survival (DFS) rate was higher in the CIA group compared with the non-CIA group in hormonal receptor-positive patients (78.4% vs. 67%, respectively; P = 0.022), and the 10-year overall survival (OS) rate also was higher in the CIA group compared with the non-CIA group (90.8% vs. 79.7%, respectively; P = 0.041). Conclusions: The most important predictors of CIA are age and the addition of tamoxifen to the chemotherapy. CIA is likely to have an influence on DFS and OS in premenopausal patients with breast cancer with a positive hormone receptor, and it might be used as a surrogate marker for effective chemotherapy in these young Asian patients.

AB - Background: We investigated the factors that predict chemotherapy-induced amenorrhea (CIA) and the prognostic significance of CIA after long-term follow-up. Methods: We reviewed data from 241 premenopausal patients with breast cancer who underwent adjuvant CMF or FAC chemotherapy after breast cancer surgery between January 1995 and December 2000. Results: The median follow-up duration was 109.8 (range, 16.6-193.1) months. The age of CIA patients was older than non-CIA patients (median, 44 (range, 28-53) years and 36 (range, 25-49) years, respectively; P < 0.001). The addition of tamoxifen to the chemotherapy increased the incidence of CIA from 48% to 63.6% (P = 0.015). The 10-year disease-free survival (DFS) rate was higher in the CIA group compared with the non-CIA group in hormonal receptor-positive patients (78.4% vs. 67%, respectively; P = 0.022), and the 10-year overall survival (OS) rate also was higher in the CIA group compared with the non-CIA group (90.8% vs. 79.7%, respectively; P = 0.041). Conclusions: The most important predictors of CIA are age and the addition of tamoxifen to the chemotherapy. CIA is likely to have an influence on DFS and OS in premenopausal patients with breast cancer with a positive hormone receptor, and it might be used as a surrogate marker for effective chemotherapy in these young Asian patients.

UR - http://www.scopus.com/inward/record.url?scp=78650984580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650984580&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1172-3

DO - 10.1245/s10434-010-1172-3

M3 - Article

VL - 17

SP - 3259

EP - 3268

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -